MedTrace Logo

Comparison of Cardiotoxicity Induced by Selective Estrogen REceptor Modulators and aNti-Aromatase

NCT03259711 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20000

Last updated 2018-10-18

No results posted yet for this study

Summary

Selective estrogen receptor modulators and aromatase inhibitors for the treatment of breast cancer seems to have an impact on the cardio-vascular system. This study investigates reports of cardiovascular toxicities for treatment including Anatomical Therapeutic Chemical (ATC) classification: L02 in the European pharmacovigilance database, Eudravigilance.

Conditions

  • Cardiac Affections

Interventions

DRUG

Hormonal therapies L02 in the ATC classification

Hormonal therapies L02 in the ATC classification

Sponsors & Collaborators

  • Groupe Hospitalier Pitie-Salpetriere

    lead OTHER

Principal Investigators

  • Joe-Elie Salem, MD, PhD · Centre Régional de Pharmaco-vigilance - Paris, Pitié-Salpétrière

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Primary Completion
2017-08-14
Completion
2017-08-14

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03259711 on ClinicalTrials.gov